In Brief | Published:

Thrombosis

Rivaroxaban, a cost-effective alternative for SVT?

Nature Reviews Cardiology volume 14, page 190 (2017) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. (2017)

Download references

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrcardio.2017.27

Authors

  1. Search for Irene Fernández-Ruiz in:

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing